Procter & Gamble Health Limited (PGHL) Fair Value & Analysis
Healthcare · IN · Market cap ₹106B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price +3.9% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹4,864 – ₹6,579 · fair‑value band ₹2,668 – ₹5,118 · the ₹6,463 price screens above the ₹3,958 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Procter & Gamble Health Limited (PGHL) currently trades at ₹6,463, while our model-based Fair Value estimate is ₹3,958 — implying the stock looks roughly 38.8% overvalued today. We read business quality at 84/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Procter & Gamble Health Limited generated revenue of ₹14.1B at a net margin of 23.2%. Revenue grew 19.1% year over year. It earns a return on equity of 61.6%. The balance sheet holds a net cash position of ₹1.8B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Procter & Gamble Health Limited reported revenue of ₹14.1B in FY2025 versus ₹11.1B in FY2021, a compound +6.0%/yr. Reported net income was ₹3.3B in FY2025, compounding +14.2%/yr from FY2021.
Is PGHL fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Procter & Gamble Health Limited (PGHL) undervalued?
What is the fair value of PGHL?
What is the quality score of PGHL?
What is the revenue of Procter & Gamble Health Limited (PGHL)?
What is the net profit margin of PGHL?
Does Procter & Gamble Health Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.